General Atlantic considers Joe & The Juice US IPO in 2026
Joe & The Juice, a juice and coffee chain founded in 2002, operated 363 locations worldwide at the end of 2023.
Its offerings include freshly prepared juices, shakes, sandwiches and coffee made with natural and organic ingredients sourced directly from growers.
Sources, who requested anonymity as the information is not public, stated that General Atlantic has been in discussions with prospective advisers regarding the listing.
A first-time share sale is expected to value Joe & The Juice at €2bn ($2.4bn).
The private equity firm may select banks for this offering later in 2025, although deliberations are ongoing and details of the IPO could still change.
General Atlantic first invested in Joe & The Juice in 2016 and acquired a majority stake in 2023 from Valedo Partners.
In December, the brand strengthened its partnership with Deliveroo by entering an exclusive partnership for the UK market.
The collaboration enabled Deliveroo customers to order the full menu for on-demand delivery in Birmingham, Brighton, Greater London, Kent, Liverpool and Oxford.
Joe & the Juice and Deliveroo first entered a partnership in 2019, covering only five UK sites. They have since expanded their collaboration to 65 locations.
The partnership supports Joe & the Juice's expansion plans, which include hundreds of new sites across the UK regions and London.
"General Atlantic considers Joe & The Juice US IPO in 2026" was originally created and published by Verdict Food Service, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
14 minutes ago
- Gizmodo
How to Self-Host n8n? An In-Depth Guide
n8n's excellence cannot be denied regarding workflow automation. Allowing you to automate repeated processes without coding, n8n speeds up and simplifies your workflows. n8n can be hosted on in-house servers. However, many are interested in self-hosting n8n. What does this mean? Instead of relying on n8n's server, the user leverages their hosting server where they install this software. The advantage is that you can choose the best n8n hosting based on your needs. This begs the question of how to self-host n8n in 2025. You'll find countless complicated and lengthy guides. However, we'll explain how to self-host n8n in the most straightforward possible manner and cover the best hosting service for this software, among other things. Table of Contents Self-hosting this automation software seems far better than using n8n's cloud servers. A glance at its subscription plans reveals relatively expensive prices. For example, the Starter plan is about $24 monthly, while the Pro plan comes at roughly $55 monthly. Both plans are billed annually, resulting in exorbitant costs right from the start. The question is: what do you get? As you can see, each plan is limited to the number of workflow executions, active workflows, shared projects, etc. The Enterprise plans virtually alleviate all 'pre-built' limits and allow you to customise them, albeit at a much higher price. So, why is self-hosting n8n better? Because you get rid of all the imposed limits. When you choose powerful n8n hosting with ample computing resources, storage, and CPU power, you can determine the number of workflow executions and active workflows. Therefore, you don't operate according to the given limits and get to use the full power of n8n. You'll still lack a few Enterprise plan features, but considering the shockingly low cost of self-hosting n8n, we think it's worth a trade-off. Another thing to consider is control. Self-hosting n8n allows for more customisation and control over the hosting environment, which many see as a notable advantage. While n8n's hosting is managed, which means automated updates and maintenance, the self-hosting way compensates with significantly lower costs. We can narrow this debate to convenience vs. customisation (control), but we prefer the latter for a highly customizable workflow automation tool. First of all, let's determine the best hosting provider. Can you host n8n on shared hosting? Even the best shared hosting is considered unfit for this workflow automation tool. Given its complexity, the software functions well on more powerful hosting types. VPS is chiefly used, although some cloud hosting services can suffice. VPS is often pricier than shared hosting and cannot be free, but that's not the point. You'll need robust, premium hosting for this case, and we wholeheartedly recommend Hostinger. Explore Hostinger n8n VPS Plans Using the links in this article, Hostinger offers special n8n-optimised VPS plans that start at only $4.99 monthly. The KVM 1 plan that bears the price tag is sufficient, although we'd go for the KVM 2 plan at $6.99 monthly with: These resources are far above what's required for self-hosting n8n, yet you're still paying roughly three times less than the n8n Starter plan. Simultaneously, Hostinger offers the convenience of easy setup and prompt deployment, so you can get started in a few minutes. Rest assured, the service is covered by a 30-day money-back guarantee if you decide to back out without consequences. Now that we've covered the basics, it's time to click the blue button to go to Hostinger's website. Learn how to self-host n8n in the following section. We clarified that the first step is a subscription to a VPS hosting service. © Hostinger will take a few minutes to create your VPS, so sit back, relax, and wait for it to finish. After that, you can access your VPS dashboard by pressing the 'Manage VPS' button. You'll see your SSH access on the right side, which you can copy and paste somewhere if you need it. Before we activate n8n, it's time to purchase a domain name. Can you get it for free? Unfortunately, Hostinger's free domain name is reserved for managed WordPress hosting. VPS subscribers don't get access to it, and while it's unnecessary for n8n hosting, most experts agree that a domain name is advisable in this case. Luckily, Hostinger lets you obtain a domain name from the abovementioned menu. Click on 'Get a Domain' to get started. You can choose the domain extension you want and generate the domain name from here. Hostinger will promptly check if the domain name is available, and if it is, you can purchase it. Now, it's time to go back to the VPS management panel. n8n will now provide you with an access key that unlocks paid features for free. Go to your email, find the license key, and copy it. Follow these steps to activate n8n: With the last step complete, you've successfully activated n8n. You can add new automation by clicking 'Add First Step' and working your way up. As you can see, self-hosting n8n is simple and requires little effort. Granted, you need to invest in a domain name, but even with this investment, you'll spend less than on n8n's solution. Hostinger has some of the cheapest web hosting plans. Similarly, its domain names are very affordable, and depending on the extension, you'll rarely spend over $15 annually. In comparison, n8n's Starter plan is way over $20 monthly. Knowing how to self-host n8n is essential for saving money and gaining more control and customisation options. While Hostinger is the #1 pick, we understand that some of you want more options. Luckily, a few more hosting services can handle n8n just as well, including: InMotion Hosting offers powerful Virtual Private Servers for self-hosting n8n. Its VPS 4 vCPU plan at $14.99 monthly comes with: In addition, you'll enjoy a free SSL certificate and two dedicated IP addresses. This plan is more than sufficient for self-hosting n8n, as it's fast, dependable, and with a nearly 100% uptime. Users can enjoy a comprehensive choice of control panels and free migrations. InMotion Hosting supports Docker, which allows for one-click app deployment. This, in turn, will enable you to set up n8n fairly simply. Moreover, InMotion's security covers DDoS protection and malware blocking, ensuring your n8n automated workflows are intact. Granted, InMotion Hosting is pricier than Hostinger, but it compensates with reliable 24/7 support that can aid the deployment and flexible VPS plans that also support Magento, Drupal, and 20+ other applications. Visit InMotion Hosting is a cheap VPS solution for n8n self-hosting. Its VPS S plan at only $6.99 monthly provides: It's a handy way of self-hosting n8n, considering the speed, convenience, and overall reliability. has a one-click app installer. It also supports Docker, which allows you to deploy n8n and start workflow automation in minutes. uses LiteSpeed web servers. Thanks to built-in caching, speeds and uptime are some of the best. cheap VPS plans are self-managed, so you'll address security and app updates. However, this means you get the highest freedom to adapt the server and its resources to your goals. has managed VPS plans, but they're multiple times pricier, making its unmanaged deals far better. Like Hostinger and InMotion Hosting, there's a 30-day money-back guarantee, which enables risk-free testing for a month, adding to its value significantly. Explore Bluehost's VPS hosting is flexible and powerful enough to handle the most complex n8n automation tasks. After all, you get full root access, which provides ample customisation and a one-click n8n setup. The Enhanced NVMe 8 plan at $65.99 monthly is the best one, with: Bluehost is surprisingly reliable. It offers AMD EPYC chips, modern hardware, and top-of-the-line security. The VPS plans allow you to host unlimited websites, while a 99.9% uptime guarantee ensures things rarely, if ever, go awry. Bluehost's ease of use is phenomenal. Apart from its one-click installer, managing installed apps is a breeze, thanks to cPanel. 24/7 support exists to pull you out of the mud if you're stuck. Bluehost's VPS plans provide DDoS protection and a free SSL. Moreover, off-site backups ensure things never get lost to oblivion. Like Hostinger and A2 Hosting, it doesn't provide a free domain in its VPS plans. The good news is that you can get one from Bluehost or purchase it via GoDaddy. The bad news is that Bluehost is costly, but if you have a deeper pocket and thicker wallet, you'll rest easy. Visit Bluehost n8n's resource requirements can range from modest to luxurious based on the usage. Simple n8n automation tasks are reported to work even on 1 GB of RAM and two CPU cores. Conversely, perplexing automation tasks require up to 8 GB of RAM and at least four CPU cores. What does this have to do with self-hosting n8n for free? There's one characteristic that connects the two sides of the spectrum. Free hosting doesn't offer them! N8n cannot be hosted for free because it won't work well on shared hosting. As explained, you'll find plenty of free web hosting services but no VPS hosting services. Even free web hosting providers are devoid of computing resources and basic features. Free VPS is also impossible, considering its characteristics, one of which is the high supply of computing resources. No one will give you that many CPU cores, RAM, and storage free of charge. Therefore, you can self-host n8n only on paid hosting servers. Don't let anyone tell you the opposite. This method of hosting n8n comes with a higher degree of responsibility. Since you don't have n8n's helping hand, it's essential to adhere to the highest security standards and keep your hosting secure. A good idea is to enable HTTPS for better encryption, use Hostinger's secure access manager, and add authentication. Hostinger recommends regular updates and patches, which, in our experience, is another vital aspect of self-hosting n8n. This is extremely simple to do through Hostinger's one-click installer. Locate the app, check for updates, and install them if needed. Lastly, remember to back up your data periodically. If n8n stops working, you can always return to a period when everything is okay. Regular backups prevent data losses, which is quintessential for keeping n8n and your business functioning correctly. Now that you know all the ins and outs of self-hosting n8n in 2025, the decision is yours. Self-hosting offers more flexibility and allows you to save plenty on n8n's in-house solution. While it's better for customisation and control, it lacks the streamlined experience you'd get from n8n's solution and its automated updates and managed security that many seem to enjoy. However, Hostinger's one-click installer simplifies deployment and provides a similar experience. Ultimately, you must choose between higher costs and more convenience or lower costs and more control. Meanwhile, you can read our in-depth Hostinger review for 2025 and decide on the next step afterwards. Self-Host n8n on Hostinger Risk-Free
Bloomberg
16 minutes ago
- Bloomberg
Indonesia's Chief Negotiator Heads to US to Discuss Tariffs
Indonesia will immediately resume tariff negotiations with the US, saying there is still a chance to bring down the 32% tariff that President Donald Trump threatens to impose starting August 1. Coordinating Minister for Economic Affairs Airlangga Hartarto, who has been leading the negotiations, is set to arrive in Washington on July 8 and then meet with US representatives, spokesperson Haryo Limanseto said in a statement on Tuesday.
Yahoo
19 minutes ago
- Yahoo
AB Science announces the successful completion of a EUR 1.925 million private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 1.925 MILLION PRIVATE PLACEMENT Paris, July 8, 2025, 8am AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 1.925 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 1,645,302 new ordinary shares in the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 2.47% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 2,41% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on July 7, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 7, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.17 (including share issue premium), representing a facial discount of 24.36% (i.e. EUR 0.38) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. July 7, 4 and 3, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 18.84% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.78 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 1,645,302 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 2.93 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of July 7, 2025, is equal to EUR 0.4392 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to July 14, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 681,937.55 (or EUR 698,390.57 in the event of exercise of all BSAs). It will be comprised of 61,431,076 ordinary shares (or of 63,076,378 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.98% on a non-diluted basis and 0.79% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on July 10, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 7, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. July 7, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). July 8, 2025 Publication of this press of the Information Document. July 10, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. July 10, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. July 14, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - AK July 2025 Press Release VEng VFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
